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A recent US case–control found an inverse association between
exposure to Hib conjugate vaccine and subsequent risk of child-
hood ALL (Groves et al, 1999). These findings were corroborated
by reanalysis of data from a clinical trial of conjugate Hib vaccine
in Finland in the 1980s (Eskola et al, 1990), which suggested that
administration of the vaccine before the first birthday, but not
after, was associated with a reduced risk of childhood ALL
(Auvinen et al, 2000). To further evaluate the possible relationship
between Hib antigen exposure and risk of ALL, the present study
compared anti-PRP concentrations in banked sera from Canadian
childhood ALL cases and matched controls. 
MATERIAL AND METHODS 
Serum selection 
Sera from 42 ALL patients were obtained from a repository of
specimens that had been collected between 1966 and 1970 from
the Hospital for Sick Children in Toronto and the Montreal
Children’s Hospital. Their median age was 5 years (range: 1 to 17
years), with 23 boys and 19 girls. Sera also were collected from 42
contemporaneous age- and sex-matched non-leukaemic hospital
controls. All 42 case–control pairs were matched on hospital and
age (± 4 years); 39 pairs also were matched on sex. The controls
included 12 children with various forms of anaemia; 7 children
suffering from complications of treatment; 4 children with coagu-
lation deficits; 4 children with rheumatic fever or its sequelae; 
3 children described only by their symptoms; 2 children with
asthma; 2 children with congenital disorders of lipid metabolism;
and 7 children with various other diagnoses (see table). 
Reagent sera with high (36.6 mgm l –1) and low (0.34 mgm l –1) anti-
Hib antibody concentrations were provided by Dr. Carl Frasch
(United States Center for Biologics Evaluation and Research,
Food and Drug Administration (CBER/FDA)). An intermediate
concentration of standard sera was prepared by mixing the high-
and low-concentration standard sera in a 1:20 ratio, for a final
concentration of 2.15 mgm l –1. In identical vials, the 84 case-
control sera were interspersed with replicates of the three 
reagent standard sera, arranged in random order, and tested under
code. 
Laboratory methods 
Hib serology was performed by the Laboratory of Vaccine
Immunology of the National Public Health Institute in Helsinki,
Finland as described (Kayhty et al, 1987; Phipps et al, 1990).
Briefly, wells of EIA plates (Costar 3591, Costar Corporation,
Cambridge MA, USA) were coated with 100 ml HbOHA antigen
(lot 15D, Dr Moon Nahm, Rochester University, Rochester, NY,
USA); 1 mgm l –1 in phosphate buffered saline (PBS). Serum
samples were diluted into PBS containing 10% of fetal calf serum
(KC Biologicals Inc, Lenexa, Kansas); and 100 ml was added into
each well. The detecting antibody was horseradish peroxidase
conjugated rabbit anti-human immunoglobulin preparation (P212,
Dakopatts, Denmark). After incubation, the substrate solution (1.1
M Na acetate in distilled water with 0.6% TMB and 30% H2O2)
was added and the reaction was stopped with 2 M H2SO4 after
incubation. The optical density (OD) was read with the Titertek
Multiskan spectrophotometer. A reference serum (lot 1983,
received from Dr Carl Frasch, CBER/FDA, Bethesda, Md)
containing 70 mg of anti-PRP ml–1 was run on each plate. The
results were given as mg of anti-PRP ml–1. The lowest detectable
concentration of anti-PRP was 0.10 mgm l –1. 
Statistical methods 
All 42 matched pairs were analysed by conditional logistic regres-
sion using SAS PROC PHREG. The 22 cases aged ≤ 5 years and
their matched controls were analysed separately, as were the 20
cases aged > five years and their matched pairs. Then the matching
was broken, and unconditional logistic regression (SAS PROC
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which the 39 subjects aged ≤ 5 years were analysed separately, as
were the 45 subjects aged > 5 years. Throughout the analysis, the
odds ratio, its 95% confidence interval, and its associated two-
sided P value, were calculated, with the low Hib antibody concen-
tration being the referent group. 
Antibody concentration then was expressed as a function of age
for the cases and controls separately, and the slopes of the regres-
sion lines were compared. A random-effects model was used to
allow for the effects of matching. When anti-PRP was unde-
tectable, a concentration of 0.05 mgm l –1 (half the lower limit of
detection) was imputed for purposes of the regression analysis. For
the ith pair, the conditional regression equation was given by 
Yij = aj + bjXij + eij, where j = 1 for the case and j = 2 for the
control, Yij was the antibody concentration and Xij was the age for
the (i,j)th child, and eij was the corresponding error term. To incor-
porate the random-effect of the ith pair, we assumed that ei1 and ei2
followed a bivariate-normal distribution with mean = 0 and
unknown dispersion matrix S. The analysis was performed using
the procedures for repeated measurements data in SAS PROC
MIXED. 
RESULTS 
The ages in years of cases (median = 5; mean = 6.29; standard
error = 0.59) and controls (median = 6; mean = 7.26; standard error
= 0.68) were similar. There were 23 male cases and 29 male
controls. Anti-PRP concentrations in the high-, intermediate-, and
low-concentration standard sera ranged from 25.42 to 45.50 mg
ml–1, from 1.53 to 3.60 mgm l –1, and from 0.28 to 0.84 mgm l –1,
respectively. Among the controls, anti-PRP was undetectable in 5
subjects but concentrations ranged up to 23.30 mgm l –1, with a
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Anaemias 12
hereditary haemolytic 8
Mediterranean 6
due to haemoglobinopathies 2
iron deficiency 1
aplastic 2
unspecified 1
Complications of... 7
...medical care 6
...surgical procedures 1
Coagulation deficits 4
haemophilia 3
other 1
Rheumatic fever and its sequelae 4
Rheumatic fever, without mention of heart involvement 2
Other heart diseases, specified as rheumatic 1
[Sydenham’s] chorea, without mention of heart involvement 1
Other diseases of blood 1
Multiple myeloma 1
Asthma 2
Congenital disorders of lipid metabolism 1
Epilepsy 1
Psoriasis and similar disorders 1
Spina bifida without mention of hydrocephalus 1
Cerebral spastic infantile paralysis 1
Anomaly of the lower limb 1
Symptoms referable to the... 3
...abdomen 1
...nervous system and senses 1
...cardiovascular and lymphatic systems 1
Diagnoses of non-leukaemic hospital control childrenmedian concentration of 0.60 mgm l –1. Among the cases, anti-
PRP was undetectable in 3 subjects but concentrations ranged 
up to 286.25 mgm l –1, with a median concentration of 0.54 mgm l –1. 
Conditional logistic regression showed no association of anti-
PRP with risk of ALL (odds ratio = 0.80, P = 0.64) when data from
children of all ages were combined. For the 22 pairs in which the
case’s age at diagnosis was ≤ 5 years, an anti-PRP concentration 
> 0.60 mgm l –1 was inversely associated with ALL (odds ratio 
= 0.29, P = 0.12). Among the 20 matched pairs in which the case
was diagnosed at age ³ 6 years, however, a high anti-PRP concen-
tration was associated with an increased risk of ALL (odds ratio 
= 2.00, P = 0.33). 
Unconditional logistic regression likewise revealed no associa-
tion of anti-PRP with risk of ALL (odds ratio = 0.83, P = 0.66)
when the unmatched data were analyzed for children of all ages.
Among 39 subjects aged ≤ 5 years, an anti-PRP concentration >
0.60 mgm l –1 was inversely associated with risk of ALL (odds ratio
= 0.25, P = 0.06). The opposite was true among the 45 subjects
over the age of 5 years, an anti-PRP concentration > 0.60 mgm l –1
was associated with an increased risk of ALL (odds ratio = 2.77, 
P = 0.12). 
When antibody concentration was expressed as a function of the
ages of the cases and controls separately, the 2 regression lines had
distinctly different slopes (P = 0.05). Inspection of Figure 1
reveals that younger cases generally had lower antibody concen-
trations than younger controls, while the opposite was true for the
older subjects. This finding was not altered by exclusion of 
one subject with an extremely high anti-PRP concentration
(286.25 mgm l –1, data not shown). 
DISCUSSION 
We found a lower risk of ALL among Canadian preschool children
with higher concentrations of anti-PRP. Among older children,
however, higher anti-PRP concentrations were associated with an
increased risk of ALL. As these sera were collected before Hib
vaccines were developed, the observed antibody concentrations
cannot be attributed to Hib vaccination, but must reflect actual
exposure to PRP from infection with Hib or cross-reacting organ-
isms. These findings suggest that early exposure to such infectious
agents may protect against childhood ALL, while delayed expo-
sure may increase the risk of ALL. Some limited evidence has
been provided for an effect of common infections on the risk of
childhood leukaemia (Greaves, 1997). Greaves has postulated 
that childhood ALL is initiated in utero, but that modulation 
of the immune system by common antigenic exposures during
early infancy can somehow suppress the expansion of the
preleukaemic cell population, whereas a delay in the antigenic
exposures to later ages may drive the preleukaemic clone to prolif-
erate, increasing the risk of subsequent childhood ALL (Greaves,
1999). 
Previous epidemiologic studies of Hib vaccine and childhood
ALL have lent support to the Greaves hypothesis. A large (n =
439) matched case–control study in the United States found a
substantially lower risk of ALL (odds ratio (OR), 0.55; 95% confi-
dence interval (CI), 0.35–0.87) among children who had been
vaccinated against Hib during the era when conjugate vaccine was
predominant (Groves et al, 1999). Because Hib vaccination was
only one of several types of early childhood vaccinations studied
and there was no clear a priori hypothesis or obvious biological
mechanism, it is unclear if the possible protective effect might be
due to the vaccination itself, to avoidance of infection, or to
chance, bias, or confounding by an unknown variable. In a
controlled clinical trial conducted in Finland (Auvinen et al, 2000),
there was a non-significant decreased risk (RR = 0.72; 95% CI =
0.46–1.13) of childhood leukaemia among subjects who received
multiple doses of Hib conjugate vaccine in the first year of life,
compared with those whose only dose was delayed until the
second birthday. 
The mechanism by which early antigenic exposures might alter the
risk of subsequent childhood ALL is unclear. Many childhood ALL
cases arise from a monoclonal expansion of cells with a characteristic
TEL-AML1 fusion gene (Wiemels et al, 1999). Twin studies have
shown that this clonal cell population may occur even in the non-
leukaemic identical twins of childhood leukaemia cases. Remarkably,
the concordance rate for leukaemia in identical twins is only about 5%
(Greaves, 1993). Thus, the TEL-AML1 fusion gene is not sufficient
for ALL, since most clones do not evolve into leukaemia. Clearly,
postnatal exposures play an important role in promoting the develop-
ment of leukaemia from the preleukemic clone. 
One weakness of the present study is that the sera were obtained
from cases only after ALL was diagnosed; thus, the anti-PRP
concentrations might have been altered by the disease process
itself. Unvaccinated leukaemic children aged 2 to 6 years at St
Jude Children’s Research Hospital had lower anti-PRP concentra-
tions than nonleukaemic children. Nonetheless, most of the
leukaemic children who had received chemotherapy for less than
12 months were still able to mount an antibody response to a
conjugate Hib vaccine, suggesting that they had not been exposed
to the PRP antigen previously (Feldman et al, 1990). Furthermore,
the older ALL cases in our study had elevated, rather than
depressed, levels of anti-PRP, again suggesting that the disease
process does not obliterate the immune response to PRP. One
strength of our study is that our sera were obtained in an era when
there were no Hib vaccines; thus, the observed anti-PRP 
concentrations must reflect actual infection with Hib or cross-
reacting organisms. The present study is consistent with the
Greaves hypothesis that early antigenic exposures protect 
against childhood ALL, while delayed exposure increases the 
risk. 
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Figure 1 Anti-PRP antibody concentration as a function of age, with fitted
curves that differed significantly (P = 0.05) between cases and controls ACKNOWLEDGEMENTS 
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